Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.
3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two enantiomers, both of which are active in vivo. In this regard, among the substituted phenethylamines, R(-)-enantiomers tend to have hallucinogen-like effects, whereas S(+)-enantiomers tend to have stimulant-like effects. In the present study, mice were trained to discriminate S(+)- or R(-)-MDMA from vehicle. Drug substitution tests were then undertaken with the structurally similar phenethylamine dopamine/norepinephrine releaser S(+)-amphetamine, the structurally dissimilar tropane nonselective monoamine reuptake inhibitor cocaine, the structurally similar phenethylamine 5-hydroxytryptamine (5-HT)(2A) agonist 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), and the structurally dissimilar mixed action tryptamine 5-HT(2A) agonist/monoamine reuptake inhibitor N,N-dipropyltryptamine (DPT). S(+)-amphetamine fully substituted in the S(+)-MDMA-treated animals but did not substitute for the R(-)-MDMA cue. 2C-T-7 fully substituted in the R(-)-MDMA-trained animals but did not substitute for the S(+)-MDMA cue. Cocaine and DPT substituted for both training drugs, but whereas cocaine was more potent in S(+)-MDMA-trained mice, DPT was more potent in R(-)-MDMA-trained mice. These data suggest that qualitative differences in the discriminative stimulus effects of each stereoisomer of MDMA exist in mice and further our understanding of the complex nature of the interoceptive effects of MDMA.
Murnane
K S
KS
Emory University, Neuroscience Graduate Program, Atlanta, Georgia, USA.
Murai
N
N
Howell
L L
LL
Fantegrossi
W E
WE
D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003042:Cocaine / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects; D004193:Discrimination Learning / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006213:Hallucinogens / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000737:chemistry / Q000494:pharmacology*; D010627:Phenethylamines / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013237:Stereoisomerism; D014363:Tryptamines / Q000494:pharmacology
D000662:Amphetamines; D000697:Central Nervous System Stimulants; D003042:Cocaine; D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D010627:Phenethylamines; D017367:Selective Serotonin Reuptake Inhibitors; D014363:Tryptamines; C487778:2,5-dimethoxy-4-n-propylthiophenethylamine; C029261:phenethylamine; C007528:dipropyltryptamine
Behav Pharmacol. 1995 Apr;6(3):263-275
11224335
Psychopharmacology (Berl). 1997 Mar;130(1):2-13
9089844
Psychopharmacology (Berl). 2005 Sep;181(3):496-503
15983786
Eur J Pharmacol. 1988 Aug 2;152(3):227-34
2906000
Annu Rev Pharmacol Toxicol. 2007;47:681-98
17209801
Neuropsychopharmacology. 1998 Oct;19(4):241-51
9718588
Pharmacol Biochem Behav. 2007 Nov;88(1):18-27
17651790
Biochem Pharmacol. 2008 Jan 1;75(1):17-33
17977517
Pharmacol Biochem Behav. 1988 Mar;29(3):443-9
2896360
J Psychopharmacol. 2006 Mar;20(2):194-210
16510478
Neuropharmacology. 1987 Nov;26(11):1657-61
2448703
Psychopharmacology (Berl). 2003 Mar;166(3):202-11
12563544
Psychopharmacology (Berl). 2005 Sep;181(3):529-36
15983787
Psychopharmacology (Berl). 1986;88(4):525-6
2871581
Drug Alcohol Depend. 1999 Aug 2;56(1):9-15
10462087
Neuropharmacology. 2001;40(1):65-74
11077072
Neuropsychopharmacology. 2000 May;22(5):513-21
10731626
Neuropsychopharmacology. 2000 Oct;23(4):396-404
10989266
Psychopharmacol Ser. 1988;4:161-75
3293041
J Pharmacol Exp Ther. 2002 Jun;301(3):1097-102
12023542
Neurosci Lett. 1994 Aug 15;177(1-2):111-5
7824160
Pharmacol Biochem Behav. 2005 Nov;82(3):531-8
16337676
Pharmacol Biochem Behav. 1999 Oct;64(2):283-93
10515304
Eur J Pharmacol. 2007 Mar 22;559(2-3):132-7
17223101
J Pharmacol Exp Ther. 2009 Jun;329(3):1006-15
19276400
Mol Pharmacol. 2003 Jun;63(6):1223-9
12761331
J Neurochem. 2007 Jul;102(1):121-32
17564678
Neuropharmacology. 1980 Aug;19(8):705-13
7422085
Pharmacol Rev. 2003 Sep;55(3):463-508
12869661